ARGX 113

Drug Profile

ARGX 113

Alternative Names: ARGX-113

Latest Information Update: 10 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator arGEN-X
  • Developer argenx
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Immune thrombocytopenic purpura; Myasthenia gravis

Most Recent Events

  • 15 Mar 2017 argenx plans a phase II proof-of-concept trial for Immune thrombocytopenic purpura
  • 15 Mar 2017 argenx plans a phase I trial in volunteers [SC]
  • 08 Feb 2017 Phase-II clinical trials in Immune thrombocytopenic purpura in Belgium, Czech Republic, France, Germany, Poland, Spain, Ukraine (IV) (NCT03102593)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top